Article

Segment 7 - Cost Considerations

Dr Peskin begins by stating, costs are exceedingly consequential. Cancer care and treatment is occupying, and with demographics being what they are, increasingly larger relative total cost of care across the US, including various national organizations.

Dr Peskin begins by stating, “costs are exceedingly consequential. Cancer care and treatment is occupying, and with demographics being what they are, increasingly larger relative total cost of care across the US,” including various national organizations.

He says insurers are working to address cost expenditures across departments as well as with surgical, medical, and radiology oncology partners. They are also including social workers and other care coordinators in that effort.

Some of the other factors payers are looking at include payment models such as bundled payments and areas of supportive care. Additionally, they are considering how to addresses the cost-effectiveness of advanced illness, compassionate care, and how to deal with patients through palliative care appropriately.

Related Videos
Image credit: Medical technology and futuristic concept. Doctor hologram modern virtual screen interface | SOMKID - stock.adobe.com
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Dr Charles Wykoff
Charles Wykoff, MD, PhD
Cathy Eng, MD, FACP, FASCO
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo